Stock Research for KMDA

KMDA

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

KMDA Stock Chart & Research Data

The KMDA chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the KMDA chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


KMDA Due diligence Resources & Stock Charts

The KMDA stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View KMDA Detailed Price Forecast - CNN Money CNN View KMDA Detailed Summary - Google Finance
Yahoo View KMDA Detailed Summary - Yahoo! Finance Zacks View KMDA Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View KMDA Trends & Analysis - Trade-Ideas Barrons View KMDA Major Holders - Barrons
NASDAQ View KMDA Call Transcripts - NASDAQ Seeking View KMDA Breaking News & Analysis - Seeking Alpha
Spotlight View KMDA Annual Report - CompanySpotlight.com OTC Report View KMDA OTC Short Report - OTCShortReport.com
TradeKing View KMDA Fundamentals - TradeKing Charts View KMDA SEC Filings - Bar Chart
WSJ View Historical Prices for KMDA - The WSJ Morningstar View Performance/Total Return for KMDA - Morningstar
MarketWatch View the Analyst Estimates for KMDA - MarketWatch CNBC View the Earnings History for KMDA - CNBC
StockMarketWatch View the KMDA Earnings - StockMarketWatch MacroAxis View KMDA Buy or Sell Recommendations - MacroAxis
Bullish View the KMDA Bullish Patterns - American Bulls Short Pains View KMDA Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View KMDA Stock Mentions - StockTwits PennyStocks View KMDA Stock Mentions - PennyStockTweets
Twitter View KMDA Stock Mentions - Twitter Invest Hub View KMDA Investment Forum News - Investor Hub
Yahoo View KMDA Stock Mentions - Yahoo! Message Board Seeking Alpha View KMDA Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for KMDA - SECform4.com Insider Cow View Insider Transactions for KMDA - Insider Cow
CNBC View KMDA Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for KMDA - OTC Markets
Yahoo View Insider Transactions for KMDA - Yahoo! Finance NASDAQ View Institutional Holdings for KMDA - NASDAQ


Stock Charts

FinViz View KMDA Stock Insight & Charts - FinViz.com StockCharts View KMDA Investment Charts - StockCharts.com
BarChart View KMDA Stock Overview & Charts - BarChart Trading View View KMDA User Generated Charts - Trading View




Latest Financial News for KMDA


Kamada Announces Preliminary Revenue for Fourth Quarter and Full-Year 2018
Posted on Wednesday January 02, 2019

Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today preliminary and unaudited total revenues for the fourth quarter and full-year 2018.  Total revenue for the fourth quarter of 2018 is expected to be between $46.7 million and $48.7 million.  Total revenue for full-year 2018 is expected to be between $113 million and $115 million. Kamada’s initial full-year 2018 total revenue guidance of $116 million to $120 million was previously revised to $102 million to $108 million as a result of the now settled labor strike at the Company’s Beit Kama production facility in Israel.


Kamada (KMDA) Reports Q3 Loss, Misses Revenue Estimates
Posted on Monday November 12, 2018

Kamada (KMDA) delivered earnings and revenue surprises of -350.00% and -42.37%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?


Kamada: 3Q Earnings Snapshot
Posted on Monday November 12, 2018

The Rehovot, Israel-based company said it had a loss of 6 cents per share. Losses, adjusted for stock option expense, came to 5 cents per share. The biopharmaceutical posted revenue of $15 million in the ...


Kamada Reports Financial Results for Third Quarter and First Nine Months of 2018
Posted on Monday November 12, 2018

Total Revenues for First Nine Months of 2018 were $66.3 Million, a 1% Decrease Year-Over-YearGross Profit for First Nine Months of 2018 was $20.2 million, a  1% Decrease.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.